The company presented new data on the PGx test this week and expressed confidence that they can secure broader payor coverage for it.
The company had total revenues of $193.5 million during the quarter, driven by continued increases in revenue and test volume for its more recently launched and acquired tests.
Genetic tests may help psychiatrists choose which drugs to start their patients on, the Wall Street Journal reports.
Positive first quarter earnings reports lifted many stocks of life science tools firms even as the broader biotechnology market suffered.
A Phase III randomized trial uncovered enhanced carboplatin response in advanced triple-negative breast cancer patients with germline mutations affecting BRCA1/2.
The lawsuits were filed after the HHS OIG subpoenaed the firm as part of an investigation into how it billed Medicare and Medicaid for the myRisk test.
The test is approved as a companion diagnostic that can determine which advanced breast cancer patients have BRCA1/2 genetic mutations and will likely respond to Lynparza.
The company has received a subpoena from HHS' OIG as part of an investigation into possible improper billing of its hereditary cancer tests to Medicare and Medicaid.
An analysis of several multigene breast cancer recurrence signatures suggests that some tests may be better than others at assessing risk of late distant recurrence.
The company discussed its efforts to grow adoption of its products during a call to discuss second quarter financial results for fiscal year 2018.
Two patients fell ill, and one subsequently died, following a fecal microbiome transplant that harbored multi-drug-resistant bacteria, according to the New York Times.
US National Institutes of Health Director Francis Collins says he will avoid male-only speaker panels.
Technology Review reports that eGenesis is testing whether organs from genetically modified pigs can be transplanted into monkeys.
In Science this week: almond reference genome, and more.